Intellia Therapeutics highlights recent company progress

Intellia Therapeutics reported operational highlights.

John Leonard MD, Intellia President and Chief Executive Officer, said: “We are off to an excellent start in 2025 with renewed focus and strong operational execution. We are excited by the clinical data presented during the fourth quarter. Our Phase 1/2 results in HAE suggest that NTLA-2002 could represent a functional cure for patients with HAE – for the first time a patient has the potential to be both free from attacks and free from chronic therapy.”

Recent operational highlights in hereditary angioedema (HAE):

• In January, Intellia announced the first patient was dosed with NTLA-2002 in the global Phase 3 HAELO study. The Company expects to complete enrollment in the second half of 2025.
• The Company plans to submit a Biologics License Application in the second half of 2026 to support plans for a U.S. launch in 2027.
• Intellia expects to present longer-term data from the ongoing Phase 1/2 study in 2025. The data will include patients in the Phase 2 portion who initially received a 25 mg dose or placebo and were subsequently given the 50 mg dose of NTLA-2002 selected for the Phase 3 study.

(Source: Intellia)